The CAR-T landscape is likely to see some movement following recent decisions in the U.K. involving NICE’s rejection of Gilead’s Yescarta and a funding deal between NHS England and Novartis for its CAR-T therapy, Kymriah.
PRMA Consulting in a recent report looks at some of the key areas to watch for developments as the industry moves forward, including how the U.S. might handle the expensive therapies.
“In the US, payers and providers use centers of excellence as a core element in providing high-quality care; for example Blue Cross Blue Shield’s Blue Distinction Specialty Care Program,” the report states. “This is forming up as an obvious approach to rolling out CAR-T therapies, starting with certified centers from clinical trials, and expanding through the existing network of accredited centers used by each payer.”
The report suggests CAR-T manufacturers must also make rigorous assessments of the safety implications, and consider the impact on health systems and budget holders.
“Manufacturers should plan to rapidly present new evidence and advance provider understanding … ,” the report states.
To read about the other key areas in the report, click here.